| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/10/2002 | US20020004477 Therapeutic administration of a modified alpha1 proteinase inhibitor |
| 01/10/2002 | US20020004247 Assay method |
| 01/10/2002 | US20020004226 Soluble LDL receptor, its production and use |
| 01/10/2002 | US20020004225 Activating bone development in mammals; prepare activator, adminster to mammal, monitor mammal for bone development |
| 01/10/2002 | US20020004224 Polypeptide; for use in the treatment of sepsis, adult respiratory distress syndrome, pancreatitis, and hemorrhagic shock |
| 01/10/2002 | US20020004215 Adjusting preferental particles to generate signal; mix ligand and marker, enzyme, incubate, allow binding, detect signal |
| 01/10/2002 | US20020004210 Calcium-independent negative regulation by cd81 of receptor signalling |
| 01/10/2002 | US20020004209 Detecting modulators of transcription; incubate cell containing human androgen and estrogen receptors, preferential protein and modulator, monitor cell for adjustment in transcriptional activity |
| 01/10/2002 | US20020004200 Amplifying preferfential cells in humans; expose human to colony stimulating factor, detect amplified cell in human |
| 01/10/2002 | US20020004073 Condensing in presence of catalytic thiol unoxidized sulfhydryl side chain of n-terminal cysteine of one oligopeptide with c-terminal thioester of other to produce intermediate bond, then rearranging to produce amide bond |
| 01/10/2002 | US20020004049 Tryptophan source from plants and uses therfor |
| 01/10/2002 | US20020004048 Hepatitis C virus asialoglycoproteins |
| 01/10/2002 | US20020004047 DNA encoding a novel RG1 polypeptide |
| 01/10/2002 | US20020004040 Complementary adenoviral vector systems and cell lines |
| 01/10/2002 | US20020004039 Stimulating proliferation of neural progenitor cells with epidermal growth factor binding polypeptide; directing migration of progeny to neurological injury sight; stimulating cell differentiation at injury |
| 01/10/2002 | US20020004037 Variant type II TGF-beta receptor fusion proteins and methods |
| 01/10/2002 | DE10031932A1 Calpain-Protease 12 Calpain protease 12 |
| 01/10/2002 | DE10030149A1 Use of novel polypeptide or its variant or nucleic acid encoding the polypeptide for diagnosing and/or preventing and/or treating skin disorders and/or treatment in wound healing or for identifying active substances |
| 01/10/2002 | CA2630062A1 Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| 01/10/2002 | CA2416191A1 Novel lipase |
| 01/10/2002 | CA2415123A1 Novel fibroblast growth factors and nucleic acids encoding same |
| 01/10/2002 | CA2415088A1 Aza-bridged-bicyclic amino acid derivatives as .alpha.4 integrin antagonists |
| 01/10/2002 | CA2414995A1 Inhibitory pas domain protein (ipas) and screening methods related to angiogenesis and tumor progression |
| 01/10/2002 | CA2414966A1 A pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration containing the component |
| 01/10/2002 | CA2414884A1 Immunisation against chlamydia pneumoniae |
| 01/10/2002 | CA2414650A1 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 01/10/2002 | CA2414635A1 Novel gonadotropin-releasing hormone, precursor peptides thereof and genes encoding the same |
| 01/10/2002 | CA2414596A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/10/2002 | CA2414592A1 Calpain protease 12 |
| 01/10/2002 | CA2414375A1 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis |
| 01/10/2002 | CA2414355A1 Amphipathic linear peptides and compositions containing same |
| 01/10/2002 | CA2414328A1 Chimeric promoters for controlling expression in smooth muscle cells |
| 01/10/2002 | CA2413756A1 Dna encoding human serine protease d-g |
| 01/10/2002 | CA2413262A1 B7-like molecules and uses thereof |
| 01/10/2002 | CA2413237A1 Alteration of cell membrane for new functions |
| 01/10/2002 | CA2413186A1 Extracellular matrix and cell adhesion molecules |
| 01/10/2002 | CA2413166A1 Acid-modified arabinogalactan protein composition |
| 01/10/2002 | CA2413158A1 Ecm-related tumor marker |
| 01/10/2002 | CA2413128A1 Transporters and ion channels |
| 01/10/2002 | CA2412882A1 Peptide extended glycosylated polypeptides |
| 01/10/2002 | CA2412872A1 Protein modification and maintenance molecules |
| 01/10/2002 | CA2412847A1 Dual recombinant gene therapy compositions and methods of use |
| 01/10/2002 | CA2412845A1 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 01/10/2002 | CA2412839A1 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd) |
| 01/10/2002 | CA2412836A1 Peptide composition for treatment of periodontal diseases and prevention of skin aging |
| 01/10/2002 | CA2411692A1 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/10/2002 | CA2410953A1 Adenylyl and guanylyl cyclases |
| 01/10/2002 | CA2410679A1 Secretion and trafficking molecules |
| 01/10/2002 | CA2410476A1 Method for treatment and prevention of mastitis |
| 01/10/2002 | CA2406649A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/09/2002 | EP1170372A1 Regulatory sequences of the human MCP-1 gene |
| 01/09/2002 | EP1170368A2 Immunization by inoculation of dna transcription unit |
| 01/09/2002 | EP1170289A2 Retroviral protease inhibiting compounds |
| 01/09/2002 | EP1170017A1 Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition |
| 01/09/2002 | EP1170016A2 Urease-based vaccine against helicobacter infection |
| 01/09/2002 | EP1169480A1 Tissue-specific and pathogen-specific toxic agents and ribozymes |
| 01/09/2002 | EP1169470A1 Methods and reagents for determining enzyme substrate specificity, and uses related thereto |
| 01/09/2002 | EP1169469A1 Human colon cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP1169465A1 Two-step immunization procedure against chlamydia infection |
| 01/09/2002 | EP1169459A1 Dsp-9 dual-specificity map kinase phosphatase |
| 01/09/2002 | EP1169456A1 Recombinant toxin a/toxin b vaccine against clostridium difficile |
| 01/09/2002 | EP1169455A1 Compounds and methods for the diagnosis and treatment of babesia microti infection |
| 01/09/2002 | EP1169451A2 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes |
| 01/09/2002 | EP1169449A2 Clasp-2 transmembrane proteins |
| 01/09/2002 | EP1169448A1 Tumor necrosis factor homologs and nucleic acids encoding the same |
| 01/09/2002 | EP1169446A2 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| 01/09/2002 | EP1169445A2 Human proteins and polynucleotides encoding them |
| 01/09/2002 | EP1169444A2 Compositions and methods for the treatment and diagnosis of breast cancer |
| 01/09/2002 | EP1169442A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2002 | EP1169441A2 Treatment of cardiac power failure using s100 proteins |
| 01/09/2002 | EP1169440A1 48 human secreted proteins |
| 01/09/2002 | EP1169438A1 Pcr-based cloning method |
| 01/09/2002 | EP1169433A1 Human hac3 |
| 01/09/2002 | EP1169351A1 Polypeptides derived from endostatin exhibiting antiangiogenic activity |
| 01/09/2002 | EP1169350A2 Human obesity protein binding protein-2 homolog compositions and uses thereof |
| 01/09/2002 | EP1169349A2 Highly purified gonadotropin compositions and process for preparing them |
| 01/09/2002 | EP1169348A1 Purposeful movement of human migratory cells away from an agent source |
| 01/09/2002 | EP1169347A2 Compounds and methods for therapy and diagnosis of lung cancer |
| 01/09/2002 | EP1169346A1 48 human secreted proteins |
| 01/09/2002 | EP1169345A2 Genes associated with diseases of the kidney |
| 01/09/2002 | EP1169344A1 47 human secreted proteins |
| 01/09/2002 | EP1169343A2 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof |
| 01/09/2002 | EP1169342A2 Tuberculosis antigens and methods of use therefor |
| 01/09/2002 | EP1169340A1 Lantibiotic |
| 01/09/2002 | EP1169339A1 Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease |
| 01/09/2002 | EP1169338A2 Low-molecular inhibitors of complement proteases |
| 01/09/2002 | EP1169334A1 48 human secreted proteins |
| 01/09/2002 | EP1169333A1 49 human secreted proteins |
| 01/09/2002 | EP1169318A1 Prodrugs of thrombin inhibitors |
| 01/09/2002 | EP1169315A2 Method for producing amidines |
| 01/09/2002 | EP1169298A2 Pharmaceutical compounds |
| 01/09/2002 | EP1169294A2 Pharmaceutical compounds |
| 01/09/2002 | EP1169069A1 Three-dimensional stromal tissue |
| 01/09/2002 | EP1169059A1 Docetaxel in combination with rhumab her2 for the treatment of cancers |
| 01/09/2002 | EP1169058A1 Insulin-like growth factor binding protein-4 protease |
| 01/09/2002 | EP1169057A2 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein |
| 01/09/2002 | EP1169056A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases |
| 01/09/2002 | EP1169055A1 Method for determining care and prevention pathways for clinical management of wounds |
| 01/09/2002 | EP1169054A2 Products and methods for treating ptp lar related diseases |
| 01/09/2002 | EP1169053A1 Pulmonary administration of dry powder formulations for treating infertility |